(Total Views: 629)
Posted On: 06/02/2024 4:41:00 PM
Post# of 148870
Re: HouseofCards #144076
CRC took the win. TNBC isn’t off the table forever but we don’t have funding for it. Until then we won’t start a trial.
“Based on the analysis of 28 mTNBC patients treated with leronlimab who had failed ≥1 line of previous therapy and its historical comparison with SOC chemotherapy treatment or Sacituzumab Govitecan (SG) treatment, including those with brain or bone metastases:
The median overall survival for patients that received leronlimab + carboplatin was greater than 12 months, regardless of brain or bone metastases, and with more than one line of previous failed therapy, which is superior to standard of care chemotherapy (6.6 months) or SG (11.8 months)
significantly longer mPFS of 6.2 months. (95% Cl: 2.6 chemotherapy in this ime sered ge of 2.3 mo tha%
Cl: 2.3 - 2.5 months) or compared to SG treatment setting of 4. months (95% Cl: 4. atones - ef tirst line
The median overall survival for patients that received higher doses (2525 mg) of leronlimab was 12+ months, regardless of brain or bone metastases, and with more than one line of previous failed therapy, which is also superior to standard of care chemotherapy and SG
92% of the patients that had measurable lesions prior to start of leronlimab had stable disease or partial response in target legions after the 1st dose of leronlimab.”
Like Jay said, we are sitting in urgent data for TNBC that is going to be published soon. As ohm pointed out it could be more about OS or that is the hope. Once the data is out do we get the funding? I don’t know.
“Based on the analysis of 28 mTNBC patients treated with leronlimab who had failed ≥1 line of previous therapy and its historical comparison with SOC chemotherapy treatment or Sacituzumab Govitecan (SG) treatment, including those with brain or bone metastases:
The median overall survival for patients that received leronlimab + carboplatin was greater than 12 months, regardless of brain or bone metastases, and with more than one line of previous failed therapy, which is superior to standard of care chemotherapy (6.6 months) or SG (11.8 months)
significantly longer mPFS of 6.2 months. (95% Cl: 2.6 chemotherapy in this ime sered ge of 2.3 mo tha%
Cl: 2.3 - 2.5 months) or compared to SG treatment setting of 4. months (95% Cl: 4. atones - ef tirst line
The median overall survival for patients that received higher doses (2525 mg) of leronlimab was 12+ months, regardless of brain or bone metastases, and with more than one line of previous failed therapy, which is also superior to standard of care chemotherapy and SG
92% of the patients that had measurable lesions prior to start of leronlimab had stable disease or partial response in target legions after the 1st dose of leronlimab.”
Like Jay said, we are sitting in urgent data for TNBC that is going to be published soon. As ohm pointed out it could be more about OS or that is the hope. Once the data is out do we get the funding? I don’t know.
(10)
(0)Scroll down for more posts ▼
